Please contact or connect with Regeneus via social media platforms below if you'd like further information.
To view the Edison Report, please visit:
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
Company Secretary and Investor Relations
Tel: +61 2 9499 8010
Fax: +61 2 9499 8020
Mob: +61 450 253 059
Regeneus Ltd (ASX:RGS) Progenza Granted Advanced Therapy Medicinal Product Designation by European Medicines Agency
Regeneus Ltd (ASX:RGS) Appoints Japan-Based Non-Executive Director with Extensive Pharmaceutical Industry Experience